Breaking the Cycle of Inflammation
An investigational oral small molecule being developed to modulate IL-1α-driven inflammation and oxidative and nitrosative stress.
The Challenge
A Cycle That Can Drive Disease
Chronic inflammation is often fueled by a self-perpetuating cycle of oxidative stress, cellular damage, and immune activation.
Learn More About the Science →The cycle continues.
Oxidative &
Nitrosative Stress
→
Nitrotyrosine
Accumulation
→
IL-1α
Release
→
Inflammation
Amplifies
→
Tissue Damage
Progresses
MIRACYLN™ is being developed to interrupt this cycle.
Our Mission
Restoring Balance. Changing Futures.
MIRACYLN™ is an investigational oral small molecule designed to modulate IL-1α-driven inflammation and reduce oxidative and nitrosative stress—before damage becomes disease.
Learn More →Development Pipeline
Advancing With Purpose
✓
DiscoveryCompleted✓
PreclinicalOngoing●
IND-EnablingStudiesPlanned
●
ClinicalDevelopmentFuture
●
RegulatoryApprovalFuture
Research
Investigating What Matters
Research involving MIRACYLN™ is ongoing. Scientific investigations continue to evaluate its potential across inflammatory, autoimmune, infectious disease, and age-related conditions.
Learn More About Our Research →Partner With Us
We are committed to advancing a new approach to inflammation and disease. Connect with our team to learn more.
⌕
ResearchersCollaborate on scientific progress♙
PartnersExplore strategic opportunities▥
InvestorsHelp advance meaningful innovation